Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Diclofenac + tizanidine** is a fixed-dose oral combination of two active ingredients: diclofenac, a non-steroidal anti-inflammatory drug (NSAID), and tizanidine, a centrally acting muscle relaxant. Diclofenac acts by inhibiting cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation and pain. Tizanidine is an alpha-2 adrenergic receptor agonist that acts at the level of the central nervous system (spinal cord and brain) to reduce excitatory input to motor neurons, subsequently relieving skeletal muscle spasticity and spasms. This combination is primarily used in the short-term management of acute musculoskeletal pain, especially when associated with muscle spasm (such as low back pain, neck pain, and other musculoskeletal conditions). The dual mechanism targets both inflammation and muscle spasticity, enhancing symptomatic relief and functional recovery. The combination should be prescribed and monitored by a physician, especially due to potential central nervous system side effects and the risk of hepatotoxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac + tizanidine.